Sort   by:  
 Page size 
UnknownThe leptomeninges as a critical organ for normal CNS development and function: First patient and public involved systematic review of arachnoiditis (chronic meningitis).
Not available
S-EPMC9524710 | biostudies-literature
UnknownEganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment.
Not available
S-EPMC11367338 | biostudies-literature
UnknownPrior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical Trial.
Not available
S-EPMC11581638 | biostudies-literature
UnknownPraluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.
Not available
S-EPMC9365353 | biostudies-literature
UnknownPredictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
Not available
S-EPMC6128180 | biostudies-literature
UnknownEffect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
Not available
S-EPMC5115200 | biostudies-literature
UnknownLongitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
Not available
S-EPMC5787203 | biostudies-literature
UnknownTemporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study.
Not available
S-EPMC7255670 | biostudies-literature
UnknownLate effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia.
Not available
S-EPMC7094022 | biostudies-literature
UnknownAbiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Not available
S-EPMC9321995 | biostudies-literature
Sort   by:  
 Page size